Format

Send to

Choose Destination
Clin Chim Acta. 2016 Jan 30;453:190-3. doi: 10.1016/j.cca.2015.12.017. Epub 2015 Dec 17.

Incidence of humoral hypercalcemia of malignancy among hypercalcemic patients with cancer.

Author information

1
Department of Pathology and Immunology, Washington University, St Louis, MO, United States.
2
Department of Pathology and Immunology, Washington University, St Louis, MO, United States. Electronic address: mscott@path.wustl.edu.

Abstract

BACKGROUND:

Malignancy-associated hypercalcemia (MAHC) is the most common cause of hypercalcemia among hospitalized patients. MAHC can result from the production of parathyroid hormone related peptide (PTHrP) which is known as humoral hypercalcemia of malignancy (HHM). HHM is commonly thought to account for approximately 80% of MAHC.

METHODS:

We conducted a 12-year review of PTHrP testing at our institution to establish the prevalence of HHM among patients with MAHC.

RESULTS:

A total of 524 PTHrP immunoassays were performed during the study period of which 470 tests qualified for inclusion in the analysis. Evidence of malignancy was found for 242 of 470 patients (51%). No etiology could be determined for 98 cases of MAHC (40%) and increased PTHrP contributed to 92 cases (38%) of MAHC. Age, race and gender were not associated with HHM. Increased PTHrP was observed at initial malignancy diagnosis in 20% of cases. PTHrP was never increased outside of the context of malignancy.

DISCUSSION:

The prevalence of HHM among patients with MAHC is likely to be lower than previously described.

KEYWORDS:

Hypercalcemia; Malignancy; PTHrP; Prevalence

PMID:
26706788
DOI:
10.1016/j.cca.2015.12.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center